Navigation Links
Study Finds Infants Under 6 Months Too Young for Flu Shot at High Risk to Influenza Fatalities- UV Technologies Makers of UV-Aid, Develop New Flu Prevention Alternative
Date:11/5/2013

Fort Myers, FL (PRWEB) November 05, 2013

A nearly decade long study documenting flu related fatalities in adolescents aged 18 and under uncovered a major gap in preventative care for children under the age of 6 months. According to the study published online in the October 28, 2013 Pediatrics Journal entitled, “Influenza-Associated Pediatric Deaths in the United States, 2004–2012”” by Karen K. Wong, MD, MPHa, Seema Jain, MDb, et al., 11% of documented children deaths were made up of infants under 6 months considered too young for preventative flu shots. Quoting the study, “Children without high-risk medical conditions were more likely to die before hospital admission (relative risk: 1.9; 95% confidence interval: 1.6–2.4) and within 3 days of symptom onset” Further the study states, “…these data which reveal that any child can be at risk of influenza associated death regardless of age or high risk medical conditions, support the recommendations that all children greater or equal to 6 months of age receive annual influenza vaccinations.”

The study fails to offer advice on alternative flu treatments for infants under the age of 6 months. The study did recommend individuals close to the infant receive flu vaccinations. With likely exposure to extended family members, friends, public areas, and daycare centers, the recommendation would be hard to follow.

According to the CDC, “For the 2013-2014 influenza season, trivalent and quadrivalent inactivated influenza vaccine (IIV) is available…IIV should not be administered to infants less than 6 months of age.” Additionally, according to the CDC, “A two-year study of children aged 6–24 months found that the vaccine was 66% effective in preventing laboratory-confirmed influenza in one year of the study (Hoberman et al., 2003). "

Kevin McGuire, President of UV Technologies, LLC and inventor of patent pending UV-Aid, states, “Flu vaccines are not 100% effective in stopping the flu and additionally vaccinations are NOT recommended for children under the age of 6 months. This leaves gap in flu protection especially for infants under the age of 6 months. Photo-oxidation provides a natural and effective option for preventing airborne diseases like the flu."

CDC data shows that during the summer seasons when photo-oxidation is highest, the occurrence of flu is 100 times less than during the winter. Further, the American Academy of Pediatrics recommends exclusive breastfeeding for the first 6 months and continued breastfeeding for at least the first year as foods are introduced.

About UV Technology, LLC:
UV Technologies, LLC’s mission is to promote health and well-being through innovative light based technologies. UV-Aid helps prevent colds, flu, sore throats, sinus and ear infections through the process of photo-oxidation. Hydrogen peroxide is produced in areas susceptible to infection. UV Technologies offers other innovative products for its customers to live a healthier and more productive life including iTanSmart, an app. that helps prevent sunburns and manage sun exposure.

Read the full story at http://www.prweb.com/releases/2013/11/prweb11294801.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. Study Suggests Vaccine May Help Kids With Brain Cancer
2. Study reveals how cancer drug causes diabetic-like state
3. Coffee Drinking in Pregnancy Wont Lead to Sleepless Baby: Study
4. Lower GI problems plague many with rheumatoid arthritis, Mayo Clinic study finds
5. Veggies Like Broccoli, Cabbage May Help Fight Breast Cancer: Study
6. No Added Cancer Risk From Hip Replacement Materials: Study
7. Reported Decline in U.S. Pneumonia Deaths May Be False: Study
8. Early Study Finds Some Promise for Lung Cancer Vaccine
9. Narcissists Often Ace Job Interviews, Study Finds
10. Sexual objectification of female artists in music videos exists regardless of race, MU study finds
11. Soy may alleviate hot flashes in menopause, large-scale study finds
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... OBISPO, Calif. (PRWEB) , ... October 13, 2017 , ... ... or dementia. However, many long-term care insurance companies have a waiver for care if ... the 90-day elimination period, when the family pays for care, is often waived, so ...
(Date:10/13/2017)... ... October 13, 2017 , ... Ellevate Network, the leading network for ... for action towards gender equality at their inaugural Summit in New York City in ... reached a social audience of over 3 million. To watch the Mobilize Women video, ...
(Date:10/13/2017)... ... 2017 , ... Yisrayl Hawkins, Pastor and Overseer at The House of Yahweh, ... and least understood books in the Holy Scriptures, Revelation. The Book of Revelation paints ... for centuries. Many have tossed it off as mere rubbish, but Yisrayl Hawkins says ...
(Date:10/13/2017)... ... 13, 2017 , ... Coveros, a leader in agile coaching ... contract by the Center for Medicare and Medicaid Services (CMS). The Enterprise Agile ... of Agile methodologies in a consistent and high value manner across CMS programs. ...
(Date:10/13/2017)... , ... October 13, 2017 , ... “America On The ... identity. “America On The Brink” is the creation of published author, William Nowers. ... great-grandchildren. As a WWII veteran, he spent thirty years in the Navy. ...
Breaking Medicine News(10 mins):
(Date:10/2/2017)... Labs announces the European launch of their new low volume, high ... in Cambridge, U.K on October 4th. The ... with unprecedented speed and sensitivity while using far less sample volume ... ... ...
(Date:9/27/2017)... 2017  Commended for their devotion to personalized service, SMP ... number one in the South Florida Business Journal,s 50 Fastest-Growing ... yearly list, the national specialty pharmacy has found its niche.  ... will soon be honored by SFBJ as the 2017 Power ... Set to receive his award in October, Bardisa said of ...
(Date:9/23/2017)... Sept. 22, 2017 Janssen Biotech, Inc. (Janssen) ... letter from the U.S. Food and Drug Administration (FDA) ... sirukumab for the treatment of moderately to severely active ... clinical data are needed to further evaluate the safety ... active RA. ...
Breaking Medicine Technology: